Tiziana Life Sciences plc, a clinical stage biotechnology company, focuses on the discovery and development of therapeutics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Milciclib (TZLS-201) that is in phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy; and Foralumab (TZLS-401), a human anti-CD3 antibody, which completed phase IIa clinical trials for autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, primary biliary cholangitis, ulcerative colitis, multiple sclerosis, autoimmune type-1 diabetes, inflammatory bowel diseases, and lupus. It also develops TZLS-501, a human anti IL-6R monoclonal antibody that is in pre-clinical development. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences plc is a subsidiary of Planwise Group Limited.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolLON:TILS
CUSIPN/A
Phone+44-20-74952379
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-457.77%
Return on Assets-208.53%
Miscellaneous
EmployeesN/A
Outstanding Shares123,830,000
Tiziana Life Sciences (LON:TILS) Frequently Asked Questions
What is Tiziana Life Sciences' stock symbol?
Tiziana Life Sciences trades on the London Stock Exchange (LON) under the ticker symbol "TILS."
How were Tiziana Life Sciences' earnings last quarter?
Tiziana Life Sciences PLC (LON:TILS) issued its quarterly earnings results on Thursday, June, 7th. The biotechnology company reported ($6.40) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($10.00) by $3.60. View Tiziana Life Sciences' Earnings History.
What price target have analysts set for TILS?
1 equities research analysts have issued twelve-month target prices for Tiziana Life Sciences' shares. Their predictions range from GBX 400 to GBX 400. On average, they anticipate Tiziana Life Sciences' share price to reach GBX 400 in the next twelve months. View Analyst Ratings for Tiziana Life Sciences.
Who are some of Tiziana Life Sciences' key competitors?
Some companies that are related to Tiziana Life Sciences include Starpharma (SPL), MediGene (MDG1), Oxford BioMedica (OXB), BioTime (BTX), Resverlogix (RVX), 22nd Century Group (XXII), Protalix Biotherapeutics (PLX), Neptune Technologies & Bioressources (NEPT), Monash IVF Group (MVF), ABcann Global (ABCN), Horizon Discovery Group (HZD), IMV (IMV), Faron Pharmaceuticals Oy (FARN), Bionomics (BNO) and Fennec Pharmaceuticals (FRX).
Who are Tiziana Life Sciences' key executives?
Tiziana Life Sciences' management team includes the folowing people:
- Mr. Gabriele Marco Antonio Cerrone, Founder & Exec. Chairman (Age 46)
- Dr. Kunwar Shailubhai, CEO, Chief Scientific Officer & Exec. Director (Age 60)
- Dr. Philip Boyd BSC, Ph.D., ACMA, Consultant
- Dr. Andrea Brancale Ph.D., Scientific Founder
- Mr. Richard Clarkson Ph.D., Scientific Founder
Has Tiziana Life Sciences been receiving favorable news coverage?
News stories about TILS stock have been trending somewhat positive on Sunday, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Tiziana Life Sciences earned a media sentiment score of 0.09 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 45.67 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
How do I buy shares of Tiziana Life Sciences?
Shares of TILS and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Tiziana Life Sciences' stock price today?
One share of TILS stock can currently be purchased for approximately GBX 38.50.
How big of a company is Tiziana Life Sciences?
Tiziana Life Sciences has a market capitalization of £122.09 million.
How can I contact Tiziana Life Sciences?
Tiziana Life Sciences' mailing address is 3rd Fl, 11-12 St. James's Square, LONDON, SW1Y 4LB, United Kingdom. The biotechnology company can be reached via phone at +44-20-74952379.
MarketBeat Community Rating for Tiziana Life Sciences (TILS)
MarketBeat's community ratings are surveys of what our community members think about Tiziana Life Sciences and other stocks. Vote "Outperform" if you believe TILS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TILS will underperform the S&P 500 over the long term. You may vote once every thirty days.
